Patents by Inventor Matthew Randolph Lee

Matthew Randolph Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240197694
    Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or modulating a DDB1- and CUL4-associated factor 1 (DCAF1) protein. Further provided herein are ligand-DCAF1 complexes or in vivo modified DCAF1 proteins.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 20, 2024
    Inventors: Jing LIU, Michael Bruno PLEWE, Matthew Randolph LEE, Xiaoran HAN, Liqun CHEN, Ting YANG, Chengwei ZHANG, Jialiang WANG
  • Patent number: 11932633
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: March 19, 2024
    Assignees: Mirati Therapeutics, Inc., Array Biopharma Inc.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, James F. Blake, Mark Joseph Chicarelli, Jay Bradford Fell, John P. Fischer, Erik James Hicken, Pavel Savechenkov, Tony Tang, Guy P. A. Vigers, Henry J. Zecca
  • Publication number: 20240066136
    Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 29, 2024
    Inventors: Jing LIU, Michael Bruno PLEWE, Matthew Randolph LEE, Xiaoran HAN, Liqun CHEN, Chengwei ZHANG, Jialiang WANG
  • Patent number: 11912719
    Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: February 27, 2024
    Assignee: Cervello Therapeutics, LLC.
    Inventors: Matthew Randolph Lee, Anthony Joseph Varano, Jr., Thomas P. Bobinski
  • Publication number: 20230137025
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: August 26, 2022
    Publication date: May 4, 2023
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • Publication number: 20230057177
    Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.
    Type: Application
    Filed: October 7, 2021
    Publication date: February 23, 2023
    Inventors: Jing LIU, Michael Bruno PLEWE, Matthew Randolph LEE, Xiaoran HAN, Liqun CHEN, Chengwei ZHANG, Jialiang WANG
  • Patent number: 11485738
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: November 1, 2022
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • Publication number: 20220119406
    Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 29, 2021
    Publication date: April 21, 2022
    Inventors: Matthew Randolph Lee, Anthony Joseph Varano, JR., Thomas P. Bobinski
  • Patent number: 11267812
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 8, 2022
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: John P. Fischer, Jay Bradford Fell, James F. Blake, Ronald Jay Hinklin, Macedonio J. Mejia, Erik James Hicken, Mark Joseph Chicarelli, John J. Gaudino, Guy P. A. Vigers, Laurence E. Burgess, Matthew Arnold Marx, James Gail Christensen, Matthew Randolph Lee, Pavel Savechenkov, Henry J. Zecca, Tony P. Tang
  • Patent number: 11248004
    Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: February 15, 2022
    Assignee: Cervello Therapeutics, LLC.
    Inventors: Matthew Randolph Lee, Anthony Joseph Varano, Jr., Thomas P. Bobinski
  • Patent number: 11220509
    Abstract: The present disclosure relates to compounds of Formula (I), or pharmaceutically, acceptable salts thereof, that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present disclosure relates to compounds, or pharmaceutically acceptable salts thereof pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising compounds of Formula (I), or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 11, 2022
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • Publication number: 20210380570
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 6, 2019
    Publication date: December 9, 2021
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, James F. Blake, Mark Joseph Chicarelli, Jay Bradford Fell, John P. Fischer, Erik James Hicken, Pavel Savechenkov, Tony Tang, Guy P.A. Vigers, Henry J. Zecca
  • Patent number: 11091495
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: August 17, 2021
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • Publication number: 20210230168
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 29, 2021
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • Publication number: 20210101904
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 8, 2021
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • Publication number: 20210032252
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 4, 2021
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • Publication number: 20200262844
    Abstract: The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: May 5, 2020
    Publication date: August 20, 2020
    Inventors: Matthew Randolph Lee, Anthony Joseph Varano, JR., Thomas P. Bobinski
  • Patent number: 10745381
    Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: August 18, 2020
    Assignee: Cervello Therapeutics, LLC.
    Inventors: Matthew Randolph Lee, Anthony Joseph Varano, Jr.
  • Publication number: 20200140412
    Abstract: The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: November 6, 2019
    Publication date: May 7, 2020
    Inventors: Matthew Randolph Lee, Anthony Joseph Varano, JR.
  • Patent number: 10266542
    Abstract: The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 23, 2019
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Robert Anthony Galemmo, Thomas P. Bobinski